Evaluation of novel particles as an inhalation system for GLP-1

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 1050-1059

  Leone Bay, A ^a   Grant, M ^a   Greene, S ^a   Stowell, G ^a   Daniels, S ^a   Smithson, A ^a   Villanueva, S ^a   Cope, S ^a   Carrera, K ^a   Reyes, S ^a   Richardson, P ^a  

^a MannKind Corporation   (United States)

Author keywords

Animal study; Diabetes therapy; GLP 1 technosphere inhalation powder; Glucagon like peptide 1; Incretin; Insulin secretion; Pharmacodynamic; Pharmacokinetic; Pulmonary administration

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FEASIBILITY STUDY; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; POWDER; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INHALATION; ANIMALS; BLOOD GLUCOSE; DRUG DELIVERY SYSTEMS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; MALE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER;

EID: 70350148542     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01096.x     Document Type: Article

References (32)

1. Kemp SF, Fielder PJ, Attie KM. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-deficient children. J Clin Endocrinol Metab 2004, 89:3234-3240.
2. Holman RR, Thorne KI, Farmer AJ. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
3. Eissele R, Göke R, Willemer S. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992, 22:283-291.
4. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24:1076-1082.
5. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965, 25:1317-1324.
6. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004, 286:E882-E890.
7. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6 week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
8. Vilsbøll T, Agersø H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
9. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003, 12:87-100.
10. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JL. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 1996, 271:E458-E464.
11. Qian F, Mathias N, Moench P. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int J Pharm 2009, 366:218-220.
12. Lee KC, Chae SY, Kim TH, Lee S, Lee ES, Youn YS. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 2009, 152:101-107.
13. Leone-Bay A, Grant M. Technosphere® technology: a platform for inhaled protein therapeutics. 2006, 11. ONdrugDelivery LTD., 8-
14. Wilson BR, Grant ML, Steiner SS, Pohl R. Technospheres for pulmonary and nasal applications. Respir Drug Deliv 2002, 2:545-548.
15. Steiner SS, Radwick AR, Jorgensen EJ. A novel glucagon delivery system for the management of hyperinsulinemia [abstract]. Diabetes 2001, 49(Suppl. 1):A368. Abstract 1545-PO
16. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere™/Insulin -proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002, 110:17-21.
17. Pfützner A, Mann AE, Steiner SS. Technosphere™/Insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002, 4:589-594.
18. Kaur N, Zhou B, Breitbeil F. A delineation of diketopiperazine self-assembly processes: understanding the molecular events involved in N€-(fumaroyl)diketopiperazine of l-Lys (FDKP) interactions. Mol Pharm 2008, 5:294-315.
19. Bergeron RJ, Phanstiel O, Yao GW, Milstein S, Weimar WR. Macromolecular self-assembly of diketopiperazine tetrapeptides. J Am Chem Soc 1994, 116:8479-8484.
20. Luo T-JM, Palmore GTR. Influence of structure on the kinetics of assembly of cyclic dipeptides into supramolecular tapes. J Phys Org Chem 2000, 13:870-879.
21. Palacin S, Chin DN, Simanek EE. Hydrogen-bonded tapes based on symmetrically substituted diketopiperazines: a robust structural motif for the engineering of molecular solids. J Am Chem Soc 1997, 119:11807-11816.
22. Palmore GTR, McBride MT. Engineering layers in molecular solids with cyclic dipeptide of (S)-aspartic acid. Chem Commun 1998, 1:145-146.
23. Bergeron RJ, Yao GW, Erdos G. An investigation of the impact of molecular geometry upon microcapsule self-assembly. J Am Chem Soc 1995, 117:6658-6665.
24. Leone-Bay A, Grant M, Rathbone M, Hadgraft J, Roberts M, Lane M. Technosphere®/Insulin: mimicking endogenous insulin release. Modified Release Drug Delivery Technology 2008, In:, eds., 2nd edn., vol 2., New York, Informa Heathcare USA, Inc.
25. Rave K, Heise T, Pfützner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere Insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007, 30:2307-2308.
26. Boss AH, Yu W, Ellerman K. Prandial insulin: is inhaled enough?. Drug Dev Res 2008, 69:138-142.
27. Pfützner A, Forst T. Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005, 2:1097-1110.
28. Rosenstock J, Bergenstal R, DeFronzo RA. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008, 31:2177-2182.
29. Cassidy J, Baughman RA, Tonelli G. Use of rapid acting insulin analog as the baseline infusion during glucose clamping improves pharmacokinetic evaluation. Diabetes 2007, 56:A159-A160.
30. Richardson PC, Boss AH. Technosphere® insulin technology. Diabetes Technol Ther 2007, 9:S65-S72.
31. Peterson RG, Shaw WN, Neel M, Little LA, Eichberg J. Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. ILAR J 1990, 32(3):16-19.
32. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006, 58:1030-1060.